DC Field | Value | Language |
---|---|---|
dc.contributor.author | B Y Kim | - |
dc.contributor.author | D W Choi | - |
dc.contributor.author | S R Woo | - |
dc.contributor.author | E R Park | - |
dc.contributor.author | J G Lee | - |
dc.contributor.author | S H Kim | - |
dc.contributor.author | I Koo | - |
dc.contributor.author | S H Park | - |
dc.contributor.author | C J Han | - |
dc.contributor.author | S B Kim | - |
dc.contributor.author | Young Il Yeom | - |
dc.contributor.author | Suk Jin Yang | - |
dc.contributor.author | A Yu | - |
dc.contributor.author | J W Lee | - |
dc.contributor.author | J J Jang | - |
dc.contributor.author | M H Cho | - |
dc.contributor.author | W K Jeon | - |
dc.contributor.author | Y N Park | - |
dc.contributor.author | K S Suh | - |
dc.contributor.author | K H Lee | - |
dc.date.accessioned | 2017-04-19T10:03:51Z | - |
dc.date.available | 2017-04-19T10:03:51Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1471-2164 | - |
dc.identifier.uri | 10.1186/s12864-015-1472-x | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/12592 | - |
dc.description.abstract | Background: Despite the recent identification of several prognostic gene signatures, the lack of common genes among experimental cohorts has posed a considerable challenge in uncovering the molecular basis underlying hepatocellular carcinoma (HCC) recurrence for application in clinical purposes. To overcome the limitations of individual gene-based analysis, we applied a pathway-based approach for analysis of HCC recurrence. Results: By implementing a permutation-based semi-supervised principal component analysis algorithm using the optimal principal component, we selected sixty-four pathways associated with hepatitis B virus (HBV)-positive HCC recurrence (p < 0.01), from our microarray dataset composed of 142 HBV-positive HCCs. In relation to the public HBV- and public hepatitis C virus (HCV)-positive HCC datasets, we detected 46 (71.9%) and 18 (28.1%) common recurrence-associated pathways, respectively. However, overlap of recurrence-associated genes between datasets was rare, further supporting the utility of the pathway-based approach for recurrence analysis between different HCC datasets. Non-supervised clustering of the 64 recurrence-associated pathways facilitated the classification of HCC patients into high- and low-risk subgroups, based on risk of recurrence (p < 0.0001). The pathways identified were additionally successfully applied to discriminate subgroups depending on recurrence risk within the public HCC datasets. Through multivariate analysis, these recurrence-associated pathways were identified as an independent prognostic factor (p < 0.0001) along with tumor number, tumor size and Edmondson's grade. Moreover, the pathway-based approach had a clinical advantage in terms of discriminating the high-risk subgroup (N = 12) among patients (N = 26) with small HCC (<3 cm). Conclusions: Using pathway-based analysis, we successfully identified the pathways involved in recurrence of HBV-positive HCC that may be effectively used as prognostic markers. | - |
dc.publisher | Springer-BMC | - |
dc.title | Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma | - |
dc.title.alternative | Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma | - |
dc.type | Article | - |
dc.citation.title | BMC Genomics | - |
dc.citation.number | 0 | - |
dc.citation.endPage | 279 | - |
dc.citation.startPage | 279 | - |
dc.citation.volume | 16 | - |
dc.contributor.affiliatedAuthor | Young Il Yeom | - |
dc.contributor.affiliatedAuthor | Suk Jin Yang | - |
dc.contributor.alternativeName | 김부여 | - |
dc.contributor.alternativeName | 최동욱 | - |
dc.contributor.alternativeName | 우선랑 | - |
dc.contributor.alternativeName | 박은란 | - |
dc.contributor.alternativeName | 이제근 | - |
dc.contributor.alternativeName | 김수현 | - |
dc.contributor.alternativeName | 구임회 | - |
dc.contributor.alternativeName | 박선후 | - |
dc.contributor.alternativeName | 한철주 | - |
dc.contributor.alternativeName | 김상범 | - |
dc.contributor.alternativeName | 염영일 | - |
dc.contributor.alternativeName | 양석진 | - |
dc.contributor.alternativeName | 유아미 | - |
dc.contributor.alternativeName | 이재원 | - |
dc.contributor.alternativeName | 장자준 | - |
dc.contributor.alternativeName | 조명행 | - |
dc.contributor.alternativeName | 전원경 | - |
dc.contributor.alternativeName | 박영년 | - |
dc.contributor.alternativeName | 서경숙 | - |
dc.contributor.alternativeName | 이기호 | - |
dc.identifier.bibliographicCitation | BMC Genomics, vol. 16, pp. 279-279 | - |
dc.identifier.doi | 10.1186/s12864-015-1472-x | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Principal component analysis | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Recurrence-associated pathway | - |
dc.subject.keyword | Risk | - |
dc.subject.keyword | Small tumor | - |
dc.subject.local | Hepatocellular carcinomas | - |
dc.subject.local | Hepatocellular carcinoma (HCC) | - |
dc.subject.local | Hepatocellular carcinoma | - |
dc.subject.local | hepatocellular carcinoma (HCC) | - |
dc.subject.local | hepatocellular carcinoma | - |
dc.subject.local | principal component analysis (PCA) | - |
dc.subject.local | Principal Component Analysis | - |
dc.subject.local | Principal component analysis (PCA) | - |
dc.subject.local | principal component analysis | - |
dc.subject.local | principal components analysis | - |
dc.subject.local | Principal component analysis | - |
dc.subject.local | Prognosis | - |
dc.subject.local | prognosis | - |
dc.subject.local | Recurrence-associated pathway | - |
dc.subject.local | Risk | - |
dc.subject.local | Small tumor | - |
dc.description.journalClass | Y | - |
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.